Prof. Marth summarizes available and emerging therapies for recurrent/metastatic cervical cancer and provides a practical example of implementing guideline recommendations into clinical practice.1/3 Next Interview
Prof. Campos reviews the latest efficacy data for current and emerging biologic treatments in the field of recurrent/metastatic cervical cancer and considers their implications for future clinical practice.2/3 Next Interview
Prof. Vergote describes the factors to be accounted for when selecting patients for biologic therapies in recurrent/metastatic cervical cancer and shares strategies for managing adverse events associated with new and emerging biologic treatments.3/3 Take CE/CME Test
Overview & Learning Objectives
In this activity, three experts explore the evolving landscape of biologic therapies in recurrent/metastatic cervical cancer and share strategies for patient selection and adverse event management.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
This activity has been designed to meet the educational needs of oncologists, including gynaecological oncologists, involved in the management of recurrent/metastatic cervical cancer worldwide.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Prof. Christian Marth discloses: Advisory board fees from AstraZeneca, GlaxoSmithKline, MSD, Roche and Seagen; speakers bureau fees from Novartis.
Prof. Susana Campos discloses: Advisory board fees from Astrazeneca, Boston Biomedical Inc., Eisai Co., Ltd. and Merck; education activity fees from Eisai Co., Ltd. and Merck.
Prof. Ignace Vergote discloses: Consulting fees from Amgen Europe GmbH, AstraZeneca, Carrick Therapeutics, Clovis Oncology, Deciphera Pharmaceuticals, Inc., Elevar Therapeutics, Genmab, GlaxoSmithKline, ImmunoGen, Inc., Jazz Pharmaceuticals, Mersana Therapeutics, Millennium Pharmaceuticals, Inc., MSD, Novocure, OCTIMET Oncology NV, Oncoinvent AS, Roche, SOTIO a.s, Verastem Oncology and Zentalis Pharmaceuticals; research support from Amgen, Genmab, Oncoinvent AS and Roche; expenses from Amgen, AstraZeneca, MSD, Roche and Tesaro.
Walter Murray Yarbrough, MD, FACP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Hennah Patel, MPharm, RPh, has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 19 May 2021. Date credits expire: 19 May 2022.
After watching this activity, participants should be better able to:
- Describe current and emerging immunotherapy approaches for the treatment of recurrent/metastatic cervical cancer
- Recall the latest clinical efficacy data for biologic therapies in recurrent/metastatic cervical cancer
- Discuss selection of biologic therapies for patients with recurrent/metastatic cervical cancer, adverse event management and future directions for treatment guidelines